Clinical trial
LMB-2 to Treat Hairy Cell Leukemia
NCT00321555 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00321555 |
|---|---|
| Title | LMB-2 to Treat Hairy Cell Leukemia |
| Official title | A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hairy Cell Leukemia |
| Intervention type | Drug |
| Interventions | Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin |
| Enrollment | 15 |
| Start date | May 2, 2006 |
| Primary completion | Aug 24, 2016 |
| Completion | Dec 31, 2022 |
| First posted | May 4, 2006 |
| Last update posted | Nov 14, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: